-

Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Wolfe Research’s 2nd Annual Virtual Healthcare Conference, which will be webcast on Wednesday, November 18, 2020. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will answer questions about the company at 9:15 a.m. EST.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Bristol Myers Squibb
Media:
media@bms.com

Investor Relations:
Tim Power
609-252-7509
timothy.power@bms.com
Nina Goworek
908-673-9711
nina.goworek@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference
Release Versions

Contacts

Bristol Myers Squibb
Media:
media@bms.com

Investor Relations:
Tim Power
609-252-7509
timothy.power@bms.com
Nina Goworek
908-673-9711
nina.goworek@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma...

Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025...

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared......
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.